Document:

Exhibit 4.1

                         COMMON STOCK PURCHASE WARRANTS

                       GREEN PLAINS RENEWABLE ENERGY, INC.

                Incorporated Under the Laws of the State of Iowa

No. - _________                                           _________ Common Stock
                                                               Purchase Warrants

                          CERTIFICATE FOR COMMON STOCK
                                PURCHASE WARRANTS

         GREEN PLAINS RENEWABLE ENERGY, INC., a Iowa corporation (the
"Company"), for value received, hereby certifies that ___________________, or
registered assigns (the "Holder"), is the registered owner of the above
indicated number of Warrants. One (1) Warrant entitles the Holder to purchase
1/4 of a share of the Company's common stock, $.001 par value (the "Common
Stock"). The Common Stock issuable upon an exercise of this Warrant is sometimes
herein referred to as the "Warrant Stock" and the shares of such Warrant Stock
are sometimes herein referred to as the "Warrant Shares."

         1. Purchase Price. The purchase price (the "Exercise Price") per share
for the Warrant Stock shall be $30.00 per share, subject to adjustment
hereunder, tendered to the Company as provided in Section 3 hereof.

         2. Rights to Exercise. The Holder shall have the right (but not the
obligation) to exercise the Warrant, in whole in or in part, to receive the
Warrant Stock, subject to adjustment hereunder, at any time on or before
December 31, 2007 (the "Exercise Period").

         3. Manner of Exercise. In order to exercise this Warrant, the Holder
shall surrender this Warrant certificate at the office of the Company, as set
forth below, or at such other address within the State of Iowa as the Company
shall designate in writing, together with a duly executed exercise form in the
form attached hereto and simultaneous payment in full (in cash or by certified
or official bank or bank cashier's check payable to the order of the Company or
by offset of obligations then owed by the Company to the Holder) of the purchase
price for the Warrant Stock. Fractional shares will not be issued upon the
exercise of Warrants, and no payment will be made with respect to any fractional
share of common stock to which any warrant holder might otherwise be entitled
upon exercise of Warrants.

         Upon surrender of this Warrant certificate in conformity with the
foregoing provisions, the Company shall promptly deliver to or upon the written
order of the Holder a stock certificate or certificates representing the Warrant
Stock.

         4. Adjustments upon Certain Events.

                  4.1 Stock Splits, Stock Combinations and Certain Stock
Dividends. If the Company shall at any time subdivide or combine its outstanding
Common Stock, or declare a dividend in Common Stock or other securities of the
Company convertible into or exchangeable for Common Stock, a Warrant shall,
after such subdivision or combination or after the record date for such
dividend, be exercisable for that number of shares of Common Stock and other
securities of the Company that the Holder would have owned immediately after
such event with respect to the Common Stock and other securities for which a
Warrant may have been exercised immediately before such event had the Warrant
been exercised immediately before such event. Any adjustment under this Section
4.1 shall become effective at the close of business on the date the subdivision,
combination or dividend becomes effective.

<PAGE>

                  4.2 Adjustment for Reorganization, Consolidation, Merger. In
case of any reorganization of the Company (or any other corporation the stock or
other securities of which are at the time receivable upon exercise of a Warrant)
or in case the Company (or any such other corporation) shall merge into or with
or consolidate with another corporation or convey all or substantially all of
its assets to another corporation or enter into a business combination of any
form as a result of which the Common Stock or other securities receivable upon
exercise of a Warrant are converted into other stock or securities of the same
or another corporation, then and in each such case, the Holder of a Warrant,
upon exercise of the purchase right at any time after the consummation of such
reorganization, consolidation, merger, conveyance or combination, shall be
entitled to receive, in lieu of the shares of Common Stock or other securities
to which such Holder would have been entitled had he exercised the purchase
right immediately prior thereto, such stock and securities which such Holder
would have owned immediately after such event with respect to the shares Common
Stock and other securities for which a Warrant may have been exercised
immediately before such event had the Warrant been exercised immediately prior
to such event.

                  4.3 Notice. In each case of an adjustment in the Common Stock
or other securities receivable upon the exercise of a Warrant, the Company shall
promptly notify the Holder of such adjustment. Such notice shall set forth the
facts upon which such adjustment is based.

         5. Loss, Theft, Destruction, or Mutilation. Upon receipt by the Company
of evidence reasonably satisfactory to it of the ownership of and the loss,
theft, destruction or mutilation of this Warrant and (in the case of loss,
theft, or destruction) of indemnity satisfactory to it (in the exercise of its
reasonable discretion), and (in the case of mutilation) upon surrender and
cancellation thereof, the Company will execute and deliver, in lieu thereof, a
new Warrant in the same form and tenor.

         6. Reservation of Shares Issuable on Exercise of Warrant. The Company
will at all times reserve and keep available out of its authorized shares,
solely for issuance upon the exercise of the Warrant, such shares of its Common
Stock and other securities as from time to time shall be issuable upon the
exercise of the Warrant.

         7. Miscellaneous.

                  7.1 Governing Law. This Warrant shall be construed in
accordance with, and governed by the substantive laws of, the State of Iowa.

                  7.2 Assignment. The benefit of this Warrant and of the Warrant
Stock represented hereby may be assigned and transferred by the Holder and its
assigns in accordance with any applicable securities laws and regulations;
however, the obligations of the Company and its successors may not be delegated
without the prior written consent of the Holder hereof. Subject to the
foregoing, this Warrant shall be binding upon and inure to the benefit of the
parties and their respective legal representatives, successors, agents, heirs
and assigns.

                  7.3 Enforcement. In the event of a dispute between the parties
arising under this Warrant, the party prevailing in such dispute shall be
entitled to collect such party's costs and expenses from the other party,
including without limitation court costs and reasonable attorneys' fees.

                  7.4 Notices. All notices, requests, consents and demands shall
be given to the Company at 9635 Irvine Bay Court, Las Vegas, NV 89147, and to
the Holder at the address shown on the records of the Company as provided by the
Holder. All notices, requests, consents and demands shall be given or made by
personal delivery, by confirmed air courier, by telecopy or by certified first
class mail, return receipt requested, postage prepaid, to the party addressed as
aforesaid. If sent by confirmed air courier, such notice shall be deemed to be
given on the earlier to occur of the date actually received by the addressee or
the business day on which delivery is made at such address as confirmed by the
air courier. If mailed, such notice shall be deemed to be given on the earlier
to occur of the date actually received by the addressee or the third business
day following the date upon which it is deposited in a first-class
postage-prepaid envelope in the United States mail addressed to such party's
business address. If given by telecopy, such notice shall be deemed to be given
on the business day actually received by the addressee.

                                       2
<PAGE>

                  7.5 Payment of Taxes. The Holder shall pay all documentary,
stamp or similar taxes and other government charges that may be imposed with
respect to the issuance, transfer or delivery of any Warrant Stock on exercise
of the Warrants. In the event the Warrant Stock are to be delivered in a name
other than the name of the Holder of the Warrant Certificate, no such delivery
shall be made unless the person requesting the same has paid the amount of any
such taxes or charges incident thereto.

                  7.6 Reduction in Exercise Price at Company's Option. The
Company's Board of Directors may, at its sole discretion, reduce the Exercise
Price of the Warrants in effect at any time either for the life of the Warrants
or any shorter period of time determined by the Company's Board of Directors.
The Company shall promptly notify the Registered Holders of any such reduction
in the Exercise Price.

         IN WITNESS WHEREOF, the Company has caused this Warrant to be duly
executed as of the ____ day of ________________, 2005.

                                            GREEN PLAINS RENEWABLE ENERGY, INC.,
                                            a Iowa corporation

                                            By: ________________________________
                                            Its: President

                                       3
<PAGE>

                       GREEN PLAINS RENEWABLE ENERGY, INC.

The following abbreviations, when used in the inscription on the face of this
instrument, shall be construed as though they were written out in full according
to applicable laws or regulations:

         TEN COM - as tenants in common
         TEN ENT - as tenants by the entireties
         JR TEN - as joint tenants with right of survivorship and not as tenants
                  in common
         UNIF TRANS MIN ACT - ____________ (Custodian for Minor) as custodian
         for __________ (name of minor) under the Uniform Transfers to Minors
         Act

Additional abbreviations may also be used though not in the above list.

                               FORM OF ASSIGNMENT

              (To be Executed by the Registered Holder if He or She
                   Desires to Assign Warrants Evidenced by the
                           Within Warrant Certificate)

         FOR VALUE RECEIVED ___________________________ hereby sells, assigns
and transfers unto _____________________________ _________________________
(_______) Warrants, evidenced by the within Warrant Certificate, and does hereby
irrevocably constitute and appoint _______________________________________
Attorney to transfer the said Warrants evidenced by the within Warrant
Certificates on the books of the Company, with full power of substitution.

Dated:____________________                         _____________________________
                                                              Signature

Notice:  The above signature must correspond with the name as written upon the
         face of the Warrant Certificate in every particular, without alteration
         or enlargement or any change whatsoever.

Signature Guaranteed: __________________________________________

SIGNATURE MUST BE GUARANTEED BY A COMMERCIAL BANK OR MEMBER FIRM OF ONE OF THE
FOLLOWING STOCK EXCHANGES: NEW YORK STOCK EXCHANGE, PACIFIC COAST STOCK
EXCHANGE, AMERICAN STOCK EXCHANGE, OR MIDWEST STOCK EXCHANGE.

<PAGE>

                          FORM OF ELECTION TO PURCHASE

           (To be Executed by the Holder if Holder Desires to Exercise
                 Warrants Evidenced by the Warrant Certificate)

To Green Plains Renewable Energy, Inc.

         The undersigned hereby irrevocably elects to exercise
___________________________ (______) Warrants, evidenced by the within Warrant
Certificate for, and to purchase thereunder, ____________________________
(______) full shares of Common Stock issuable upon exercise of said Warrants and
delivery of $_________ and any applicable taxes.

         The undersigned requests that certificates for such shares be issued in
the name of:

PLEASE INSERT SOCIAL SECURITY OR TAX IDENTIFICATION NUMBER

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
                         (Please print name and address)

--------------------------------------------------------------------------------

         If said number of Warrants shall not be all the Warrants evidenced by
the within Warrant Certificate, the undersigned requests that a new Warrant
Certificate evidencing the Warrants not so exercised be issued in the name of
and delivered to:

--------------------------------------------------------------------------------
                         (Please print name and address)

--------------------------------------------------------------------------------

Dated: _____________________                Signature:__________________________

NOTICE:  The above signature must correspond with the name as written upon the
         face of the within Warrant Certificate in every particular, without
         alteration or enlargement or any change whatsoever, or if signed by any
         other person the Form of Assignment hereon must be duly executed and if
         the certificate representing the shares or any Warrant Certificate
         representing Warrants not exercised is to be registered in a name other
         than that in which the within Warrant Certificate is registered, the
         signature of the holder hereof must be guaranteed.

Signature Guaranteed: ___________________________________________

SIGNATURE MUST BE GUARANTEED BY A COMMERCIAL BANK OR MEMBER FIRM OF ONE OF THE
FOLLOWING STOCK EXCHANGES: NEW YORK STOCK EXCHANGE, PACIFIC COAST STOCK
EXCHANGE, AMERICAN STOCK EXCHANGE, OR MIDWEST STOCK EXCHANGE.QuickLinks
 -- Click here to rapidly navigate through this document
  

Exhibit 10.16  

 
 

EXCLUSIVE PURCHASE AND SUPPLY AGREEMENT    
    

        This EXCLUSIVE PURCHASE AND SUPPLY AGREEMENT (hereinafter "Agreement"), is made and entered into as of this 14th day of August, 2002, by and between  Imagenetix, Inc., a California corporation with its principal place of business located at 16935 West Bernardo Drive, Suite 101, San
Diego, California 92127 (hereinafter "IMAGENETIX" or "Seller"); and Clincyte, Inc./Cymbiotics, a California corporation with its principal
place of business at PO BOX 910047, California 92191 (hereinafter "CLINCYTE" or "Buyer"). 

WITNESSETH  

        Whereas, IMAGENETIX is a corporation duly organized, validly existing, and in good standing under the laws of the State of California, and has the ability and
experience to produce and supply certain types of raw materials, including certain nutritional and health-related items, including those which contain or pertain to the Cetyl Myristoleate and the CM
Complex ("RAW MATERIAL"). 

        Whereas
CLINCYTE is a corporation duly organized, validly existing, and in good standing under the laws of the State of California and has the ability and experience to and has the
ability and experience to market and distribute health-related items; and Whereas, CLINCYTE desires to have the RAW MATERIAL that IMAGENETIX has, owns and manufactures and also manufactures
formulations from the RAW MATERIAL into tablets or capsules and ointments ("PRODUCT"), and whereas IMAGENETIX also distributes and sells the PRODUCT throughout the United States and Canada. 

        Whereas
CLINCYTE wants to formulate the RAW MATERIAL into tablets and ointment ("PRODUCT") and distribute PRODUCTS in the Indian Sub Continent, the pacific rim countries including
Malaysia, Singapore, Thailand, Philippines, Japan, Turkey, Israel and Middle East, South
Africa and Brazil ("MARKET SEGMENTS"). (Indian Sub Continent would be an exclusive for CLINCYTE, in their channel of distribution (ie: hospitals and clinics, as a therapeutic product)). 

        Whereas
CLINCYTE wants to sell the formulations to hospitals and clinics as a therapeutic product, using the retail markets or agents in Malaysia, Singapore, and Japan. In India, Israel,
Brazil, Turkey, Middle East, South Africa and the Philippines, CLINCYTE wants to sell formulations to hospitals, clinics and pharmacies ("Field of Use"). Whereas CLINCYTE will be responsible to obtain
all the regulatory permits in each of the target countries including the expenses involved in obtaining such permits. 

        Now,
therefore, it is agreed as follows: 

        1.     Supply and Purchase of the Product.

	(a)
	IMAGENETIX
will supply the Product to CLINCYTE, which will be in the form of a powder and oil that is E. Coli and Salmonella free and in the same form IMAGENETIX is using in its
tablet/capsule formulations. IMAGENETIX will also provide CLINCYTE the exact specifications for the tablet and capsule formulations and the exact specifications and formulations that are in the
ointment.

	(b)
	CLINCYTE
agrees to purchase the Product exclusively from IMAGENETIX or until superceded by subsequent written agreements. IMAGENETIX will supply the RAW MATERIALS in shipment approved
25 KG plastic containers that keep the RAW MATERIAL dry and in drums (for the oil) that would be 170 kgs. 

1

 

        2.     Marketing and Sales.

	(a)
	CLINCYTE
shall use its best efforts and due diligence to market, promote and sell the Product, which at this time is expected to be promoted as an anti-inflammatory supplement used in
treating Osteo-arthritis.

	(b)
	The
scientific and professional staff of IMAGENETIX shall be accessible to CLINCYTE staff, as well as to its prospective and existing clients to offer consultation and advice
regarding product safety and other scientific clarification, as needed. Such consultation may take the form of conference calls as well as travel to prospective client's sites or offices.

	(c)
	CLINCYTE
will only sell the PRODUCTS to hospitals and clinics as a therapeutic product. They will do this by using the retail markets, or agents, in Malaysia, Singapore, and Japan. In
India, Israel, Brazil, Turkey, Middle East, South Africa, Thailand and the Philippines, ClinCyte will sell formulations to hospitals, clinics and pharmacies. No sales will take place in the United
States, nor will any client of CLINCYTE sell into the United States, from the aforementioned list of countries. 

        3.    Compliance with Laws.    IMAGENETIX shall be responsible for compliance with all laws and regulations with
respect to its manufacture and sale of the RAW MATERIAL and all liability insurance. CLINCYTE will not be responsible for unapproved marketing claims or marketing statements. IMAGENETIX will carry
insurance to protect its own business activities. CLINCYTE will carry insurance to protect its own business activities. 

        4.    Labeling.    CLINCYTE may use any of the names, which are used to describe the Product line referred to herein
on any sign, label or other advertising during the term of this Agreement. Labeling material will include appropriate warnings regarding those who should use the Product with caution, or for whom the
Product may be contra-indicated, and will also include directions as to proper storage. CLINCYTE may trade mark protect these names in the specific markets and will own such trademarks. 

        5.     Right to Cancel Without Notice.

        (a)    Right of IMAGENETIX.    In the case where CLINCYTE is declared by a court of competent jurisdiction insolvent
or bankrupt, or in the case a receiver or trustee is appointed for CLINCYTE, IMAGENETIX may, at its option, cancel this Agreement without any notice to CLINCYTE. 

        (b)    Right of CLINCYTE.    In the case where IMAGENETIX is declared by a court of competent jurisdiction insolvent
or bankrupt, or in the case a receiver or trustee is appointed for IMAGENETIX, CLINCYTE may, at its option, cancel this Agreement without any notice to IMAGENETIX. 

        6.    Requirements to Maintain Exclusivity.    CLINCYTE'S fiscal year shall be used for all sales calculations but no
minimum purchase shall be required at anytime. However, in order to maintain exclusivity, CLINCYTE will be required to have an initial purchase of 2000kg of the Product from IMAGENETIX within a
three-year period. CLINCYTE shall not be subject to penalty, billing, cost or damages should it fail to meet the above purchase requirement to maintain exclusivity. 

        7.    Term.    Each party to this Agreement and the rights granted hereby shall remain and continue in full force and
effect for a period of Three (3) years, commencing January 1, 2003, (Effective date for meeting milestones) and subject to the following: 

	(a)
	Buyer
and Seller have an option for a three (3) year renewal term after the initial agreement period expires on December 31, 2005. The term will be
automatically renewed on December 31, 2005 for an additional period of three (years) if CLINCYTE meets the minimum purchase of the raw material from IMAGENETIX specified in section 6
above.

2

 

	(b)
	If
any Product shipments from IMAGENETIX are unable to be delivered for 30 days after the initial down-payment is made and written notice is given by CLINCYTE to IMAGENETIX either by
telegram, telex, or registered mail, or if IMAGENETIX is in default in performing any of the other terms of this Agreement including failure to deliver the Product in the form specified, and such
default continues for a period of 30 days after written notice thereof is given to IMAGENETIX, then CLINCYTE shall have the right to immediately terminate this Agreement without waiver of its other
rights. 

        8.    Placement of Orders.    CLINCYTE will place orders for Products by one of the following methods. 

	(a)
	By
sending via ordinary mail a purchase order utilizing IMAGENETIX's then-current purchase order form, or

	(b)
	By
transmitting the order to IMAGENETIX by telephone, telex, cable, wire, telecopier, telegram or similar means of telecommunication.

	(c)
	IMAGENETIX
reserves the right to accept only orders that are within the scope of its availability to deliver. Only orders for which an advance payment has been Made as specified in
item 10 a, b and c will be considered legally binding. 

        9.     Price and Price Changes.

        The
price for the RAW MATERIALS, free of all federal, state and local taxes on the sale or shipping of the Products, shall be as follows: 

	(a)
	per
 kilogram for the oil (Product A) and              (Product B) per kilogram for the powder with a discount
 of               of Product A is ordered within a single fiscal year
 and              discount if              of Product
B is ordered.

	(b)
	All
pricing is F.O.B. Southern California.

	(c)
	The
price set forth above is for a period of three years and a price adjustment (upwards or downwards) may be made based on the performance milestones by CLINCYTE and or the inflation
rate in the third year of this agreement. 

        10.   Payment and Delivery  

	(a)
	Payment
and delivery terms are as follows for all orders of 1,000 kilos or less. Any orders greater than 1,000 kilos will be secured by a letter of credit or handled on a case-by-case
basis:

	i.
	On the first order: a 50% down-payment on the first order at the time of order and payment in full within thirty (30) days
of delivery of order.

	ii.
	On the second order: a 40% down-payment on the Second order at the time of order and payment in full within thirty (30)
days of delivery of order

	iii.
	On the third order: a 30% down-payment on the third order at the time of order and payment in full within thirty (30) days of delivery
of order

	iv.
	On the fourth order: a 20% down-payment on the fourth order at the time of order and payment in full within thirty (30) days of
delivery of order

	v.
	On all subsequent orders: a 10% down-payment on all subsequent order at the time of order and payment in full within thirty (30) days of
delivery of order 

3

 

	(b)
	Buyer
shall pay seller a late fee of 10% per annum penalty on all outstanding balances until payment is received in full.

	(c)
	Delivery
of the product after the initial down payment has been received will take place within 30 days. Seller shall pay Buyer a late fee of 10% per annum on those funds received for
any Product not delivered within said 30 days. 

        11.    Shipment of Orders.    IMAGENETIX shall deliver Products according to the shipping terms, Product
specifications and other instructions specified by CLINCYTE herein and in each Purchase Order, to the specified FOB point and upon the date or within the time period specified. It is understood and
agreed by IMAGENETIX that time is of the essence and accordingly IMAGENETIX shall inform CLINCYTE by telephone, telecopier or the quickest means available if it cannot deliver Products according to
the specified delivery schedule. 

        12.    Shipping Costs, Title and Risk of Loss.    Delivery of Products shall be F.O.B. Southern California. All costs
for shipping from IMAGENETIX's manufacturing plant in Southern California to any other point appointed by CLINCYTE shall be borne by CLINCYTE. All costs of shipping insurance shall be borne by
IMAGENETIX to the F.O.B. point. 

        13.   Acceptance and Rejection of Products.  

	(a)
	Acceptance.
CLINCYTE shall determine whether to accept or reject Products delivered by IMAGENETIX (based on meeting the standards set forth in 1a) as soon as reasonably practicable,
and CLINCYTE shall be deemed to have accepted Products if it does not notify IMAGENETIX in writing of its rejection within thirty (30) days of Products arrival at the F.O.B. point. CLINCYTE may, at
its option, reject all or any Products delivered for one or more of the additional following grounds

	(i)
	Should
Products be shipped in quantities substantially less or greater than the amount specified by CLINCYTE or otherwise not in conformance with this Agreement and the
purchase order;

	(ii)
	Should
Products be defective, damaged or otherwise unfit for their intended use, Acceptance of all or any portion of Products by CLINCYTE shall not be deemed a waiver
of its right at any time to cancel or return all or any part-thereof or exercise any other rights hereunder because the Products do not comply with CLINCYTE's specifications or governmental
regulations, or by reason of either patent or latent defects or breach of warranty by IMAGENETIX.

	(b)
	Non-delivery;
Rejection of Products; Partial Acceptance. If Seller fails to make delivery or repudiates or if Buyer rightfully rejects all or any portion of the Products contained in
a shipment, then with respect to any Products involved, Buyer may cancel the shipment and recover the price paid for said rejected Products. On a rightful rejection, Buyer shall have a security
interest in Products in its possession or control for any payments made on their price and any expenses reasonably incurred in their inspection, receipt, transportation, care, and custody. 

        14.   Seller's Representations, Warranties and Covenants.  

	(a)
	Seller
expressly warrants that all Products sold hereunder shall meet all specifications set forth herein and shall also be of merchantable quality, free from defects in material and
workmanship, fully acceptable, fit for their intended use and, to the extent legally required, approved by the Federal Food and Drug Administration, United States Department of Agriculture, or any
other federal, state or local governmental agency having jurisdiction over 

4

 

the
Product; that all Products will be shipped in accordance with applicable federal, state and local laws, regulations and orders, and applicable industry standards. Should federal, state, local
regulatory or applicable industry requirements specify defect limits or other requirements that are more stringent than those, if any, specified by CLINCYTE, the more stringent requirements shall
prevail and apply. No Product contained in any shipment now or hereafter made to Buyer will, at time of shipment or delivery, be adulterated, misbranded or mislabeled within the meaning of any
applicable federal, state or municipal law, as such exist at the time of shipment or delivery. This warranty shall be a continuing warranty and shall be binding upon Seller with respect to all
Products that Seller ships or delivers to Buyer or Buyer's customers (including Product in transit). 

	(b)
	Upon
request, Seller shall furnish Buyer certificates of compliance with (i) all applicable laws, orders and regulations, whether federal, state, or municipal, or agency
thereof, which apply to this Agreement and (ii) the written formulations and specifications for Product.

	(c)
	Seller
shall be required to return any and all Buyers' funds advanced to Seller for any product lost or destroyed in shipment within 30 days. 

        15.   Relationship of the Parties.  

        Neither party shall be, nor represent in any manner, express or implied, that it is an employee, agent, partner, legal representative, or joint venturer of the
other party. Without in any way limiting the generality of the foregoing, neither party shall have the right or authority to pledge the credit of the other, create or assume any obligation in the name
of the other party, or otherwise bind the other party in any way. 

        16.   Responsibilities of the Parties.  

        Each party assumes all responsibility for and shall bear all liabilities and expenses relating to the respective parties' activities and acts as they relate to
and affect the product. 

        17.    Arbitration.    Any controversy or claim arising out of or relating to this Agreement, or the breach thereof,
shall be settled by arbitration in San Diego County, the State of California, in accordance with the Commercial Arbitration Rules of the American Arbitration Association, and judgment upon the award
rendered by the Arbitrators) may be entered in any court having jurisdiction thereof. 

        18.    Confidentiality.    The parties mutually acknowledge that during the term of this Agreement, CLINCYTE may
disclose to IMAGENETIX certain confidential and/or proprietary information concerning CLINCYTE's marketing, promotion, sales, customers, or other plans and that IMAGENETIX may disclose to CLINCYTE
certain confidential and/or proprietary information concerning IMAGENETIX's method of conducting business or other plans. Both parties agree to keep all such information confidential from outsiders
and to disclose such information within the respective companies only on a "need to know" basis. 

5

 

        19.    Notices.    Any notice, request, demand, or other communication required or permitted hereunder shall be deemed
to be properly given when deposited in the United States mail, as follows: 

	(a)
	Mr.
William Spencer, President

Imagenetix, Inc.

16935 West Bernardo Drive, Suite 101

San Diego, CA 92127

	(b)
	Dr.
Raj Barathur, President

ClinCyte/Cymbiotics

PO BOX 910047

San Diego, CA 92191 

        20.    Completeness of Instrument.    This instrument contains all of the agreements, understandings, representations,
conditions, warranties, and covenants made between the parties hereto. Unless set forth herein, neither party shall be liable for any representations made, and all modifications and amendments hereto
must be in writing. 

        21.    Assignment.    This Agreement constitutes a personal contract and IMAGENETIX shall not transfer or assign the
Agreement or any part thereof without the written consent of CLINCYTE. 

        22.    No Implied Waivers.    The failure of either party at any time to require performance by the other party of any
provision hereof shall not affect in any way the full right to require such performance at any time thereafter. Nor shall the waiver by either of a breach of any provision hereof be taken or held to
be a waiver of the provision itself. 

        23.    Controlling Law.    The validity, interpretation, and performance of this Agreement shall be controlled by and
construed under the laws of the State of California, the state in which this Agreement is being executed. 

        24.    Benefit.    This Agreement shall be binding upon and insure to the benefit of the heirs, legal representatives,
successors, and assigns of the parties hereto; provided, however, the rights granted to CLINCYTE hereunder shall not be assignable or transferable without the prior written consent of IMAGENETIX. 

        In
witness whereof the parties have executed this Agreement. 

	IMAGENETIX, INC.	 	 	 	 
	By:	 	/s/ Bill Spencer	 	Date:	 	10-16-2002
	 	 	
	 	 	 	

	Bill Spencer CEO and President	 	 	 	 
	
CLINCYTE, INC./CYMBIOTICS	
 	

 	
 	

 
	By:	 	/s/ Raj Barathur	 	Date:	 	10-16-2002
	 	 	
	 	 	 	

	Chairman	 	 	 	 

6

AMENDMENT TO EXCLUSIVE PURCHASE AND SUPPLY AGREEMENT  

        The following amendments are being made and entered into on the 8th day of March, 2004 to an exclusive purchase and supply agreement of raw
materials namely Esterified Fatty Acid Complex (hereinafter "EFAC") that was executed on October 11, 2002 between Imagenetix Inc., a California corporation with its principal place of business
located at 16935 West Bernardo Drive, Suite 101, San Diego, California 92127 (hereinafter "IMAGENETIX" or "Seller"); and Cymbiotics, a California corporation with its principal place of
business at 3910 Stonebridge Ln, Rancho Santa Fe, CA 92091 (hereinafter "Cymbiotics" or "Buyer"). 

Recitals  

	1.
	In
an exclusive agreement between IMAGENETIX and CYMBIOTICS that was executed on October 11, 2002, the prices agreed upon were $50.00/kg for the EFAC
powder and $60.00/kg for the EFAC Oil. All pricing in the original agreement was based on FOB Southern California.

	2.
	All
orders were to be executed based on a purchase order and the payment terms established was 50% upfront payment on first order and the balance in 30 days after shipment was received
by CYMBIOTICS. On subsequent orders the up front payments was gradually reduced from 40% to 10% on all subsequent orders with balance due in 30 days after shipment was received by CYMBIOTICS.

	3.
	CYMBIOTICS
was provided an exclusive manufacturing, marketing, distribution agreement in some selected countries and the products were to be sold in the ethical markets and to
hospitals, Physicians, Clinics and Pharmacies.

	4.
	CYMBIOTICS
uses a contract manufacturer in the countries it will be selling the formulations. The Contract Manufacturer identified in India is VVS Pharma located in Hyderabad, India or
other such Contract Manufacturer identified by CYMBIOTICS in writing to IMAGENETIX. 

        Now,
therefore, IMAGENETIX and CYMBIOTICS have agreed to the following amendments to the said agreement executed on October 11, 2002. 

Amendments  

	1.
	IMAGENETIX
hereby agrees to sell and supply the raw materials for $40.00/kg for the EFAC powder and $50.00/kg for the EFAC oil. This
amendment to the pricing will be valid for 1 year from the date of delivery and receipt of the first commercial shipment by CYMBIOTICS. Pricing will be reviewed 30 days before expiry of this 1 year.

	2.
	IMAGENETIX
also amends the payment terms. IMAGENETIX agrees to accept payments based on a Letter of Credit issued by CYMBIOTICS and or its contract manufacturer drawn against a US
bank. CYMBIOTICS and or its contract manufacturer will release an irrevocable letter of credit issued by a international bank in India or other countries with IMAGENETIX as the beneficiary.

	3.
	CYMBIOTICS
and or its contract manufacturer will purchase a 90 day irrevocable Letter of Credit that can be used by IMAGENETIX an instrument to take a loan on the LOC prior to
expiration of the 90 day period for which the bank charges a nominal interest of LIBOR plus 1 to 2%. CYMBIOTICS and or its contract manufacturer will pay this interest to IMAGENETIX and will be
included in the purchase order and the Letter of Credit.

	4.
	CYMBIOTICS
and or its contract manufacturer will also include the shipping charges in the Letter of Credit.

	5.
	IMAGENETIX
will ship the EFAC in 30 kg approved containers within 7-10 days of receipt of the purchase order and the Letter of Credit. 

        IMAGENETIX
and CYMBIOTICS further agree that no other changes to the original agreement have been made or implied and all the covenants in the agreement remain intact and in full force.
The amendment to the original Agreement shall be binding upon and inure to the benefit of the heirs, legal representatives, successors, and assigns of the parties hereto; provided, however, the rights
granted to CYMBIOTICS hereunder shall not be assignable or transferable without the prior written consent of IMAGENETIX. 

        In
witness whereof the parties have executed this Agreement. 

	IMAGENETIX, INC.	 	 	 	 
	By:	 	/s/ Bill Spencer	 	Date:	 	3-8-04
	 	 	
	 	 	 	

	Bill Spencer CEO and President	 	 	 	 
	
CYMBIOTICS, INC.	
 	

 	
 	

 
	By:	 	/s/ Raj Barathur	 	Date:	 	8th March 2004
	 	 	
	 	 	 	

	Raj Barathur PhD CEO and President	 	 	 	 
	Fax #: 858-759-7667	 	 	 	 

QuickLinks

EXCLUSIVE PURCHASE AND SUPPLY AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}]]